Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/50764

Type
Article
Copyright
Open access
Collections
Share

Statistics
Metadata
Show full item record

REPURPOSING THE EBOLA AND MARBURG VIRUS INHIBITORS TILORONE, QUINACRINE, AND PYRONARIDINE: IN VITRO ACTIVITY AGAINST SARS-COV‑2 AND POTENTIAL MECHANISMS
Puhl, Ana C. et al. | Date Issued: 2021
Author
Puhl, Ana C.
Fritch, Ethan James
Lane, Thomas R.
Tse, Longping Victor
Yount, Boyd L.
Sacramento, Carolina de Queiroz
Rodrigues, Natalia Fintelman
Tavella, Tatyana Almeida
Costa, Fabio Trindade Maranhão
Weston, Stuart
Logue, James
Frieman, Matthew
Premkumar, Lakshmanane
Pearce, Kenneth H.
Hurst, Brett L.
Andrade, Carolina Horta
Levi, James A.
Johnson, Nicole J.
Kisthardt, Samantha C.
Scholle, Frank
Souza, Thiago Moreno Lopes e
Moorman, Nathaniel John
Baric, Ralph S.
Madrid, Peter B.
Ekins, Sean
Affilliation
Collaborations Pharmaceuticals, Inc. Raleigh, NC, USA.
University of North Carolina. School of Medicine. Department of Microbiology and Immunology. Chapel Hill, NC, USA.
Collaborations Pharmaceuticals, Inc. Raleigh, NC, USA.
University of North Carolina. School of Medicine. Department of Epidemiology. Chapel Hill, NC, USA.
University of North Carolina. School of Medicine. Department of Epidemiology. Chapel Hill, NC, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnológico em Saúde. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnológico em Saúde. Rio de Janeiro, RJ, Brasil.
Universidade Estadual de Campinas. Instituto de Biologia. Departamento de Genética e Evolução, Microbiologia e Imunologia. Laboratório de Doenças Tropicais. Campinas, SP, Brasil.
Universidade Estadual de Campinas. Instituto de Biologia. Departamento de Genética e Evolução, Microbiologia e Imunologia. Laboratório de Doenças Tropicais. Campinas, SP, Brasil.
University of Maryland. School of Medicine. Department of Microbiology and Immunology. Baltimore, MD, USA.
University of Maryland. School of Medicine. Department of Microbiology and Immunology. Baltimore, MD, USA.
University of Maryland. School of Medicine. Department of Microbiology and Immunology. Baltimore, MD, USA.
University of North Carolina. School of Medicine. Department of Microbiology and Immunology. Chapel Hill, NC, USA.
University of North Carolina. Eshelman School of Pharmacy. Chemical Biology and Medicinal Chemistry. Center for Integrative Chemical Biology and Drug Discovery. Chapel Hill, NC, USA / University of North Carolina. Lineberger Comprehensive Cancer Center. Chapel Hill, NC, USA.
Utah State University. Institute for Antiviral Research. Logan, UT, USA / Utah State University. Department of Animal, Dairy and Veterinary Sciences. Logan, UT, USA.
Universidade Estadual de Campinas. Instituto de Biologia. Departamento de Genética e Evolução, Microbiologia e Imunologia. Laboratório de Doenças Tropicais. Campinas, SP, Brasil / Universidade Federal de Goiás. Faculdade de Farmácia. Laboratório de Planejamento de Fármacos e Modelagem Molecular. Goiânia, GO, Brasil.
North Carolina State University. Department of Biological Sciences. Raleigh, NC, USA.
North Carolina State University. Department of Biological Sciences. Raleigh, NC, USA.
North Carolina State University. Department of Biological Sciences. Raleigh, NC, USA.
North Carolina State University. Department of Biological Sciences. Raleigh, NC, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnológico em Saúde. Rio de Janeiro, RJ, Brasil.
University of North Carolina. School of Medicine. Department of Microbiology and Immunology. Chapel Hill, NC, USA / University of North Carolina. Eshelman School of Pharmacy. Chemical Biology and Medicinal Chemistry. Center for Integrative Chemical Biology and Drug Discovery. Chapel Hill, NC, USA / University of North Carolina. Rapidly Emerging Antiviral Drug Discovery Initiative. Chapel Hill, NC, USA.
University of North Carolina. School of Medicine. Department of Microbiology and Immunology. Chapel Hill, NC, USA / University of North Carolina. School of Medicine. Department of Epidemiology. Chapel Hill, NC, USA / University of North Carolina. Rapidly Emerging Antiviral Drug Discovery Initiative. Chapel Hill, NC, USA.
Stanford Research Institute International. Menlo Park, CA, USA.
Collaborations Pharmaceuticals, Inc. Raleigh, NC, USA.
Abstract
Severe acute respiratory coronavirus 2 (SARS-CoV-2) is a newly identified virus that has resulted in over 2.5 million deaths globally and over 116 million cases globally in March, 2021. Small-molecule inhibitors that reverse disease severity have proven difficult to discover. One of the key approaches that has been widely applied in an effort to speed up the translation of drugs is drug repurposing. A few drugs have shown in vitro activity against Ebola viruses and demonstrated activity against SARS-CoV-2 in vivo. Most notably, the RNA polymerase targeting remdesivir demonstrated activity in vitro and efficacy in the early stage of the disease in humans. Testing other small-molecule drugs that are active against Ebola viruses (EBOVs) would appear a reasonable strategy to evaluate their potential for SARS-CoV-2. We have previously repurposed pyronaridine, tilorone, and quinacrine (from malaria, influenza, and antiprotozoal uses, respectively) as inhibitors of Ebola and Marburg viruses in vitro in HeLa cells and mouse-adapted EBOV in mice in vivo. We have now tested these three drugs in various cell lines (VeroE6, Vero76, Caco-2, Calu-3, A549-ACE2, HUH-7, and monocytes) infected with SARS-CoV-2 as well as other viruses (including MHV and HCoV 229E). The compilation of these results indicated considerable variability in antiviral activity observed across cell lines. We found that tilorone and pyronaridine inhibited the virus replication in A549-ACE2 cells with IC₅₀ values of 180 nM and IC₅₀ 198 nM, respectively. We used microscale thermophoresis to test the binding of these molecules to the spike protein, and tilorone and pyronaridine bind to the spike receptor binding domain protein with Kd values of 339 and 647 nM, respectively. Human Cₘₐₓ for pyronaridine and quinacrine is greater than the IC₅₀ observed in A549-ACE2 cells. We also provide novel insights into the mechanism of these compounds which is likely lysosomotropic.
Keywords in Portuguese
Atividade In Vitro contra SARS-CoV‑2
Reaproveitando
Inibidores do vírus Ebola e Marburg Tilorone
Quinacrina e Pironaridina
Mecanismos Potenciais
 
Keywords
Vitro Activity against SARS-CoV‑2
Repurposing
Ebola and Marburg Virus
Inhibitors Tilorone, Quinacrine, and Pyronaridine
Potential Mechanisms
 
Publisher
American Chemical Society
Citation
PUHL, Ana C. et al. Repurposing the Ebola and Marburg virus inhibitors tilorone, quinacrine, and pyronaridine: in vitro activity against SARS-CoV‑2 and potential mechanisms. ACS Omega, v. 6, n. 11, p. 7454-7468, 23 Mar. 2021.
Previous version
https://www.arca.fiocruz.br/handle/icict/50788
DOI
10.1101/2020.12.01.407361
ISSN
2470-1343
Notes
Produção científica do Laboratório de Imunofarmacologia.